Table 3.
Kidney transplant recipient characteristics, stratified by DGF
| Recipient Characteristics | All (n=2435) | DGF (n=756) | Non-DGF (n=1679) |
|---|---|---|---|
| Age, y | 53 (15) | 55 (13) | 52 (16) |
| Male gender | 1493 (61%) | 496 (66%) | 997 (59%) |
| Black race | 959 (39%) | 371 (49%) | 588 (35%) |
| Hispanic ethnicity | 279 (11%) | 79 (10%) | 200 (12%) |
| Donor AKI | |||
| No AKI | 1849 (76%) | 517 (68%) | 1332 (79%) |
| Stage 1 | 392 (16%) | 136 (18%) | 256 (15%) |
| Stage 2 | 109 (4%) | 53 (7%) | 56 (3%) |
| Stage 3 | 85 (3%) | 50 (7%) | 35 (2%) |
| Cause of ESRD | |||
| Diabetes | 718 (29%) | 231 (31%) | 487 (29%) |
| Hypertension | 657 (27%) | 227 (30%) | 430 (26%) |
| Other or unknown | 504 (21%) | 136 (18%) | 368 (22%) |
| GN | 394 (16%) | 109 (14%) | 285 (17%) |
| Graft failure | 162 (7%) | 53 (7%) | 109 (6%) |
| HLA mismatch level | |||
| 0 | 153 (6%) | 27 (4%) | 126 (8%) |
| 1 | 21 (1%) | 11 (1%) | 10 (1%) |
| 2 | 83 (3%) | 20 (3%) | 63 (4%) |
| 3 | 292 (12%) | 91 (12%) | 201 (12%) |
| 4 | 644 (27%) | 192 (25%) | 452 (27%) |
| 5 | 822 (34%) | 270 (36%) | 552 (33%) |
| 6 | 414 (17%) | 144 (19%) | 270 (16%) |
| Panel reactive antibody | |||
| 0% | 1549 (64%) | 501 (66%) | 1048 (62%) |
| 1%–20% | 178 (7%) | 59 (8%) | 119 (7%) |
| 21%–80% | 326 (13%) | 89 (12%) | 237 (14%) |
| >80% | 382 (16%) | 107 (14%) | 275 (16%) |
| Cold ischemia time, h | 15.28 (7.09) | 17.21 (7.14) | 14.42 (6.90) |
| Preemptive transplant | 274 (11%) | 28 (4%) | 246 (15%) |
| Serum creatinine at transplant, µmol/L | 686 (296) | 746 (285) | 659 (297) |
Values reported are mean (SD) or n (%). Stage 1 AKI was defined as an increase in serum creatinine of ≥26.5 µmol/L or an increase of 1.5-fold from admission to terminal value. Stage 2 was defined as an increase of between two- and three-fold from baseline. Stage 3 was defined as an increase of three-fold from baseline or a serum creatinine of ≥354 µmol/L. HLA, human leukocyte antigen.